CONFERENCES

      sbv Improver

      These are events held by the sbv Improver consortium to identify novel methods for the analysis of epigenomic data, with topics ranging from epigenomic data to machine learning. The events are aimed at bringing together experts from academia, industry, and government, and provide a forum for sharing knowledge and collaborating to identify future trends in the application of the sbv Improver. 

      Epigenomics Challenge 2017

      Date

      May 04, 2017

      Location

      Tel Aviv, Israel

      This is a closing Symposium for sbv IMPROVER Challenge, where invited keynote speakers give presentations, as well as the challenge winners who present their submission. During this event, PMI scientists share a proof of concept database and website hosting results from inhalation studies, with the aim of assessing potential modified-risk tobacco products (MRTP). 

      See related presentations

      Systems Toxicology Symposium 2016

      Date

      Mar 15, 2016 - Mar 17, 2016

      Location

      New Orleans, USA

      The Systems Toxicology Symposium’s objective is to present to a panel of experts the results of preclinical and clinical assessment studies conducted by Philip Morris International R&D and to capture the opinion of the panel in a SciPi™. SciPi™ is short for SCIentific oPInion. Run by SciPinion, a SciPi™ is a specialized survey for scientists to weigh in with their opinion on important topics. In this instance, the SciPi™ will involve attending a short oral presentation as well as getting more insight from posters, in order to answer questions on the interpretation of preclinical and clinical findings about a Reduced-Risk Product (RRP*) prototype. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.